Show simple item record

dc.contributor.authorJackaman, Connie
dc.contributor.authorNelson, Delia
dc.date.accessioned2017-03-15T22:03:48Z
dc.date.available2017-03-15T22:03:48Z
dc.date.created2017-02-24T00:09:08Z
dc.date.issued2012
dc.identifier.citationJackaman, C. and Nelson, D. 2012. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ - independent resolution of treated-turmors and CD4+ -dependent systemic and memory responses. Cancer Immunology, Immunotherapy. 61: pp. 549-560.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/49275
dc.description.abstract

Targeting interleukin-2 (IL-2) and/or agonist anti-CD40 antibody (Ab) into tumors represents an effective vaccination strategy that avoids systemic toxicity and resolves treated-site tumors. Here, we examined IL-2 and/or anti-CD40 Ab-driven local versus systemic T cell function and the installation of T cell memory. Single tumor studies showed that IL-2 induced a potent CD4? and CD8? T cell response that was limited to the draining lymph node and treated-site tumor, and lymph node tumorspecific CD8? T cells did not upregulate CD44. A twotumor model showed that while IL-2-treated-site tumors resolved, distal tumors continued to grow, implying limited systemic immunity. In contrast, anti-CD40 Ab treatment with or without IL-2 expanded the systemic T cell response to non-draining lymph nodes, and distal tumors resolved. Tumor-specific T cells in lymph nodes of anti-CD40 Ab ± IL-2-treated mice upregulated CD44, demonstrating activation and transition to effector/memory migratory cells. While CD40-activated CD4? T cells were not required for eradicating treated-site tumors, they, plus CD8? T cells, were crucial for removing distal tumors. Rechallenge/depletion experiments showed that the effector/memory phase required the presence of previously CD40/IL-2-activated CD4? and CD8? T cells to prevent recurrence. These novel findings show that different T cell effector mechanisms can operate for the eradication of local treated-site tumors versus untreated distal tumors and that signaling through CD40 generates a whole of body, effector/memory CD4? and CD8? T cell response that is amplified and prolonged via IL-2. Thus, successful immunotherapy needs to generate collaborating CD4? and CD8? T cells for a complete long-term protective cure.

dc.publisherSpringer
dc.relation.urihttp://link.springer.de/link/service/journals/00262/index.htm
dc.subjectTumor immunity
dc.subjectMemory
dc.subjectCD8? T cells
dc.subjectCD4? T cells
dc.titleIntratumoral interleukin-2/agonist CD40 antibody drives CD4+ - independent resolution of treated-turmors and CD4+ -dependent systemic and memory responses
dc.typeJournal Article
dcterms.source.volume61
dcterms.source.startPage549
dcterms.source.endPage560
dcterms.source.issn0340-7004
dcterms.source.titleCancer Immunology, Immunotherapy
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record